Apremilast 20mg
CC-10004-PSA-002
Phase 3 small_molecule completed
Quick answer
Apremilast 20mg for Psoriatic Arthritis is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Psoriatic Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed